We are live on ! Find out more
MESO

Mesoblast

69 hedge funds and large institutions have $50.5M invested in Mesoblast in 2026 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 25 increasing their positions, 16 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

755% more call options, than puts

Call options by funds: $24.8M | Put options by funds: $2.9M

56% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 16

0.72% less ownership

Funds ownership: 3.27%2.55% (-0.72%)

7% less funds holding

Funds holding: 7469 (-5)

23% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 13

33% less capital invested

Capital invested by funds: $75.7M → $50.5M (-$25.1M)

Holders
69
Holders Change
-5
Holders Change %
-6.76%
% of All Funds
0.85%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
10
Increased
25
Reduced
16
Closed
13
Calls
$24.8M
Puts
$2.9M
Net Calls
+$21.9M
Net Calls Change
-$17.5M

MESO Hedge Fund Activity: Q1 2026 in Review

69 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Mesoblast (MESO) for Q1 2026, worth a combined $50.5M — down 33% from $75.7M a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of MESO and 10 opened new positions — a net loss of 3 holders — while 16 trimmed existing stakes and 25 added.

The largest buyer was Bank of America, adding an estimated $1.43M. The largest seller was Legal & General Group, exiting entirely with an estimated $12.2M sold.

  • 69 institutional investors held Mesoblast (MESO) as of Q1 2026, down from 74 in Q4 2025.
  • Funds reported $50.5M of Mesoblast stock for Q1 2026, down 33% quarter-over-quarter.
  • 10 funds opened new Mesoblast positions in Q1 2026 and 13 closed out, a net change of -3 holders.
  • The largest Mesoblast buyer in Q1 2026 was Bank of America, an estimated $1.43M added.
  • The largest Mesoblast seller in Q1 2026 was Legal & General Group, an estimated $12.2M sold.

Based on aggregated 13F filings for Q1 2026.